What is BRENZAVVY prescribed for?
BRENZAVVY is prescribed to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
What is the name of the drug and what does it do?
BRENZAVVY, pronounced bren-ZA-vee, (generic name: bexagliflozin) , is used to improve blood sugar control in adults with type 2 diabetes. It helps manage diabetes when combined with diet and exercise.
How does it work?
BRENZAVVY works by inhibiting a protein in the kidneys called SGLT2. This protein reabsorbs glucose back into the bloodstream.
By blocking SGLT2, BRENZAVVY causes excess glucose to be excreted in the urine, thereby lowering blood sugar levels.
What did the research discover?
The FDA approved BRENZAVVY based on evidence from nine clinical trials involving 4,462 adults.
These trials showed that BRENZAVVY significantly lowered HbA1c levels, which is a measure of blood sugar control over the past 8 to 12 weeks.
The trials were conducted globally, including in the United States and several other countries.
What are some of the side effects?
The side effects listed are from the product manufacturer. As health scientists, we share this information to keep you informed without causing undue worry. Many side effects diminish over time, and not all patients experience them. If prescribed medication, take it as directed and consult your healthcare professional if you have any concerning side effects.
- Increased urination
- Urinary tract infections
- Genital yeast infections
- Vaginal itching
- Hypoglycemia (when used with insulin or insulin-secreting drugs)
- Lower blood pressure
What are the dosage recommendations and how is it prescribed?
BRENZAVVY is taken as a tablet once daily in the morning, with or without food.
The exact dosage should be prescribed by a healthcare provider based on individual needs and health status.
Source:
- FDA. Drug Trials Snapshots: BRENZAVVY. Available from: FDA website
- Highlights of Prescribing Information for BRENZAVVY. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf. Accessed 16 July 2024
